The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2025
Filed:
Nov. 26, 2019
Applicant:
Immunitybio, Inc., San Diego, CA (US);
Inventors:
Fereshteh Parviz, San Diego, CA (US);
Rohit Duggal, San Diego, CA (US);
Assignee:
ImmunityBio, Inc., San Diego, CA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/55 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/421 (2025.01); A61K 40/4234 (2025.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2827 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); C12N 15/85 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01); C12N 2830/001 (2013.01); C12N 2830/50 (2013.01); C12N 2840/203 (2013.01);
Abstract
Disclosed herein are recombinant nucleic acids, comprising a 5' untranslated (5′-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.